AstraZeneca (LON:AZN) Given Sell Rating at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reaffirmed by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday,Digital Look reports. They presently have a £115 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential downside of 15.29% from the stock’s current price.

A number of other analysts have also commented on AZN. Shore Capital Group reiterated a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Citigroup raised their target price on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research report on Friday, April 10th. Berenberg Bank raised their target price on AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £180 target price on shares of AstraZeneca in a research report on Friday, April 10th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of £153.33.

AstraZeneca Stock Performance

Shares of AZN stock traded up GBX 246 during trading hours on Wednesday, reaching £135.76. The company had a trading volume of 154,623,859 shares, compared to its average volume of 31,940,236. The business has a fifty day moving average price of £146.29 and a 200-day moving average price of £139.94. AstraZeneca has a one year low of GBX 9,651 and a one year high of £157.32. The firm has a market cap of £210.54 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 0.86 and a beta of 0.28. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.